You just read:

Neurocrine Announces Long-Term Results Evaluating INGREZZA® for the Treatment of Adults with Tardive Dyskinesia Published in the Journal of Clinical Psychiatry

News provided by

Neurocrine Biosciences, Inc.

Nov 14, 2017, 12:34 EST